

Suzetrigine's journey through clinical trials reflects more than scientific success—it signals a potential paradigm shift in how we treat pain. Its rapid onset and comparable performance to hydrocodone/acetaminophen place it on equal footing with opioids, but with far fewer side effects and no addictive potential. The drug's ability to consistently relieve both soft tissue and bone-related pain highlights its versatility.